
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options with no options contract fees
- Get up to $1,000 in stock when you open and fund a new account within 30 days
- Access to a financial planner
Veradigm is a health information services business based in the US. Veradigm shares (MDRX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $4.40 – the same closing value as a week prior. Veradigm employs 2,450 staff and has a trailing 12-month revenue of around $588 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Latest market close | $4.40 |
---|---|
52-week range | $3.80 - $11.80 |
50-day moving average | $4.62 |
200-day moving average | $8.13 |
Wall St. target price | $8.17 |
PE ratio | N/A |
Dividend yield | N/A |
Earnings per share (TTM) | $-0.18 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $4.4 from 2025-05-02
1 week (2025-04-25) | 4.4 |
---|---|
1 month (2025-04-04) | 10.00% |
3 months (2025-02-05) | -12.00% |
6 months (2024-11-05) | -53.29% |
1 year (2024-05-03) | -42.86% |
---|---|
2 years (2023-05-04) | -63.30% |
3 years (2022-05-04) | 20.86 |
5 years (2020-05-04) | 5.73 |
Valuing Veradigm stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Veradigm's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Veradigm's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.4237. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Veradigm's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Veradigm's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $51.7 million.
The EBITDA is a measure of a Veradigm's overall financial performance and is widely used to measure a its profitability.
Revenue TTM | $588 million |
---|---|
Operating margin TTM | 16.59% |
Gross profit TTM | $308.4 million |
Return on assets TTM | -0.62% |
Return on equity TTM | -1.69% |
Profit margin | -14.7% |
Book value | $9.59 |
Market Capitalization | $460.1 million |
TTM: trailing 12 months
We're not expecting Veradigm to pay a dividend over the next 12 months.
Over the last 12 months, Veradigm's shares have ranged in value from as little as $3.8 up to $11.8. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Veradigm's is 0.628. This would suggest that Veradigm's shares are less volatile than average (for this exchange).
Veradigm Inc. , a healthcare technology company, provides information technology solutions to healthcare providers, payers, and biopharma markets in the United States and internationally. The company offers solutions to healthcare providers, comprising practice management software, AI patient scheduling software, and electronic statements and payments, and payerpath clearinghouse; revenue cycle services and coding services; electronic health records solutions, which include eprescribe with EPCS, EHR software, veradigm EHR, and practice fusion EHR; and patient engagement platform. It also provides solutions to network partners, which comprise API connectivity solutions, such as veradigm connect, veradigm app expo, and diagnostic ordering and resulting network; life sciences, health plans and payers, and providers; and veradigm eprescribe enterprise. In addition, the company offers risk adjustment solutions, such as health equity analytics, risk adjustment analytics, risk mitigator, comprehensive submissions, and utilization analytics; quality analytics, risk adjustment, and quality management; data exchange and coding solutions, including echart courier, echart coder, and echart integration and analytics; clinical data registries for physicians and veradigm payer insights; provider engagement solutions; care gap alerting, gap closure services, and veradigm payerpath solutions. Further, it provides real world data solutions, such as NLP-enriched EHR data solutions, and clinical data registries; real world evidence and real-world evidence analytics platform; and digital health media solutions. The company was formerly known as Allscripts Healthcare Solutions, Inc.
Track the progress of the S&P 500 stocks to make more informed investment decisions.
See our picks for the best brokers for trading S&P 500 stocks, ETFs, options and futures.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
Stock lending allows investors to loan out their existing stocks, although it has both advantages and disadvantages.
Compare pros, cons, research tools and reviews for these two trading platforms.
Some of the best trading apps like Robinhood are SoFi, Tastytrade, Public, eToro, Acorns, Interactive Brokers, E*TRADE and more.
Compare pros, cons, research tools and reviews for these two trading platforms.
SoFi Invest is a no-fee commissions platform with both active and automated investment accounts.
Webull is a broker with zero-commission trading and a suite of tools to help you invest.